PVLA Palvella Therapeutics, Inc.

NASDAQ
$156.13

Palvella Therapeutics, Inc. (PVLA) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $1.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.4% since its last earnings release on August 4, 2026.

Palvella Therapeutics Missed Consensus Estimates
Tuesday, August 4, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($1.63)
Rev est $28.26M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $154.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Palvella Therapeutics, Inc.

Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow